E. Eric Tokat (@EricTokat) profile picture
Joined May 2022
Super excited about this deal! 👏👏👏 The team at Merida pioneered an innovative approach to deplete pathogenic autoantibodies for autoimmune disease and allergy. @EliLillyandCo will help make this transformative approach a reality for patients! Congrats to Adam Townsend, Dario Gutierrez, Dodzie Sogah, and the entire Merida team!
3
79
12,256
Centerview Partners acted as Exclusive Financial Advisor to Inhibrx $INBX $SNY
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B Inhibrx, Inc. shareholders will receive $30/sh in cash, a $5 CVR, 0.25 shares in New Inhibrx, a new publicly traded company that retains all non-101 assets of Inhibrx prnewswire.com/news-releases…
3
2
6
70
37,167
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B Inhibrx, Inc. shareholders will receive $30/sh in cash, a $5 CVR, 0.25 shares in New Inhibrx, a new publicly traded company that retains all non-101 assets of Inhibrx prnewswire.com/news-releases…
8
3
44
62,583
Centerview Partners acted as Exclusive Financial Advisor to Gracell on its sale to AstraZeneca
$GRCL Gracell Biotechnologies to be acquired by AstraZeneca for $10+$1.50CVR, or up to $1.2bn $AZN ir.gracellbio.com/news-relea…
3
3
2
55
32,638
$GRCL Gracell Biotechnologies to be acquired by AstraZeneca for $10+$1.50CVR, or up to $1.2bn $AZN ir.gracellbio.com/news-relea…
3
1
23
30,413
Centerview Partners acted as Exclusive Financial Advisor to Icosavax on its sale to AstraZeneca
AstraZeneca to acquire Icosavax for $15+$5; or up to $1.1bn $ICVX $AZN investors.icosavax.com/news-…
4
4
3
42
22,817
AstraZeneca to acquire Icosavax for $15+$5; or up to $1.1bn $ICVX $AZN investors.icosavax.com/news-…
5
1
23
24,458
Centerview Partners acted as financial advisor to Carmot Therapeutics
2
4
3
67
30,867